FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:445-451 February 15, 1996 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Gout is a clinical syndrome resulting from the deposition of urate (monosodium urate monohydrate) crystals. The crystals may be deposited in a joint, leading to an acute inflammatory response, or in soft tissues, such as cartilage, causing no inflammation. Most cases of gout are characterized by the sudden onset of severe acute monarticular arthritis in a peripheral joint in the leg. The arthritis remits completely and then recurs with increasing frequency. After approximately 10 years of recurrent gouty arthritis, tophi develop in cartilage, tendons, and bursae in some patients.

Established criteria for the diagnosis of gout include the presence of . . . [Full Text of this Article]

Treatment of Acute Gouty Arthritis

Colchicine

Nonsteroidal Antiinflammatory Drugs

Corticosteroids

Prophylaxis against Acute Gout

Correction of Hyperuricemia

Uricosuric Drugs

Xanthine Oxidase Inhibition

Goals of Urate-Lowering Therapy

Chronic Complicated and Unresponsive Gout

Summary

Source Information

From the University of Queensland, Department of Medicine, Princess Alexandra Hospital, Ipswich Rd., Woolloongabba, Brisbane, Queensland 4102, Australia, where reprint requests should be addressed to Dr. Emmerson.

References

Related Letters:

Management of Gout
Simkin P. A., Sarkozi J., Emmerson B. T.
Extract | Full Text  
N Engl J Med 1996; 334:1543-1544, Jun 6, 1996. Correspondence

This article has been cited by other articles:

• Anzai, N., Ichida, K., Jutabha, P., Kimura, T., Babu, E., Jin, C. J., Srivastava, S., Kitamura, K., Hisatome, I., Endou, H., Sakurai, H. (2008). Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans. J. Biol. Chem. 283: 26834-26838 [Abstract] [Full Text]  
• Singh, J A, Strand, V (2008). Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis 67: 1310-1316 [Abstract] [Full Text]  
• Williams, P. T (2008). Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am. J. Clin. Nutr. 87: 1480-1487 [Abstract] [Full Text]  
• Choi, H. K, Curhan, G. (2008). Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336: 309-312 [Abstract] [Full Text]  
• Kutzing, M. K., Firestein, B. L. (2008). Altered Uric Acid Levels and Disease States. J. Pharmacol. Exp. Ther. 324: 1-7 [Abstract] [Full Text]  
• Chang, S.-J., Tsai, P.-C., Chen, C.-J., Lai, H.-M., Ko, Y.-C. (2007). The polymorphism -863C/A in tumour necrosis factor-{alpha} gene contributes an independent association to gout. Rheumatology (Oxford) 46: 1662-1666 [Abstract] [Full Text]  
• Fitzgerald, B. T., Setty, A., Mudgal, C. S. (2007). Gout Affecting the Hand and Wrist. J Am Acad Orthop Surg 15: 625-635 [Abstract] [Full Text]  
• Choi, H. K., Mount, D. B., Reginato, A. M. (2005). Pathogenesis of Gout. ANN INTERN MED 143: 499-516 [Full Text]  
• Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., Belli, R., Trinchero, R. (2005). Colchicine in Addition to Conventional Therapy for Acute Pericarditis: Results of the COlchicine for acute PEricarditis (COPE) Trial. Circulation 112: 2012-2016 [Abstract] [Full Text]  
• Suresh, E (2005). Diagnosis and management of gout: a rational approach. Postgrad. Med. J. 81: 572-579 [Abstract] [Full Text]  
• Choi, H. K., Atkinson, K., Karlson, E. W., Curhan, G. (2005). Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in Men: The Health Professionals Follow-up Study. Arch Intern Med 165: 742-748 [Abstract] [Full Text]  
• Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., Chen, M.-J., Lai, P.-C., Wu, M.-S., Chu, C.-Y., Wang, K.-H., Chen, C.-H., Fann, C. S. J., Wu, J.-Y., Chen, Y.-T. (2005). HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102: 4134-4139 [Abstract] [Full Text]  
• Yu, K.-H., Luo, S.-F., Tsai, W.-P., Huang, Y.-Y. (2004). Intermittent elevation of serum urate and 24-hour urinary uric acid excretion. Rheumatology (Oxford) 43: 1541-1545 [Abstract] [Full Text]  
• Gardner, H, McQueen, F (2004). Tophaceous gout of the pubic symphysis: an unusual cause of groin pain. Ann Rheum Dis 63: 767-768 [Full Text]  
• Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W., Curhan, G. (2004). Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men. NEJM 350: 1093-1103 [Abstract] [Full Text]  
• Lyu, L.-C., Hsu, C.-Y., Yeh, C.-Y., Lee, M.-S., Huang, S.-H., Chen, C.-L. (2003). A case-control study of the association of diet and obesity with gout in Taiwan. Am. J. Clin. Nutr. 78: 690-701 [Abstract] [Full Text]  
• Rott, K. T., Agudelo, C. A. (2003). Gout. JAMA 289: 2857-2860 [Full Text]  
• Vazquez-Mellado, J, Morales, E M., Pacheco-Tena, C, Burgos-Vargas, R (2001). Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 60: 981-983 [Abstract] [Full Text]  
• KELLY, S. J., DELNOMDEDIEU, M., OLIVERIO, M. I., WILLIAMS, L. D., SAIFER, M. G. P., SHERMAN, M. R., COFFMAN, T. M., JOHNSON, G. A., HERSHFIELD, M. S. (2001). Diabetes Insipidus in Uricase-Deficient Mice: A Model for Evaluating Therapy with Poly(Ethylene Glycol)-Modified Uricase. J. Am. Soc. Nephrol. 12: 1001-1009 [Abstract] [Full Text]  
• Waring, W.S., Webb, D.J., Maxwell, S.R.J. (2000). Uric acid as a risk factor for cardiovascular disease. QJM 93: 707-713 [Full Text]  
• Dessein, P H, Shipton, E A, Stanwix, A E, Joffe, B I, Ramokgadi, J (2000). Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59: 539-543 [Abstract] [Full Text]  
• Garbe, E., Suissa, S., LeLorier, J. (1998). Exposure to Allopurinol and the Risk of Cataract Extraction in Elderly Patients. Arch Ophthalmol 116: 1652-1656 [Abstract] [Full Text]  
• EMMERSON, B. (1998). Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis 57: 509-510 [Full Text]  
• Perez-Ruiz, F, Alonso-Ruiz, A, Calabozo, M, Herrero-Beites, A, García-Erauskin, G, Ruiz-Lucea, E (1998). Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57: 545-549 [Abstract] [Full Text]  
• Margalit, A., Hauser, S. D., Zweifel, B. S., Anderson, M. A., Isakson, P. C. (1998). Regulation of prostaglandin biosynthesis in vivo by glutathione. Am. J. Physiol. Regul. Integr. Comp. Physiol. 274: R294-R302 [Abstract] [Full Text]  
• KANN, S. E., JACQUEMIN, J. B., STERN, P. J. (1996). Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Simulators of Hand Infections*{{dagger}}. JBJS 78: 1114-28 [Full Text]  
• Simkin, P. A., Sarkozi, J., Emmerson, B. T. (1996). Management of Gout. NEJM 334: 1543-1544 [Full Text]